{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:13:00Z","timestamp":1794103980468,"version":"4.8.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Headache disorders are a global public health concern affecting diverse populations. This review examines headache service organizations in low-, middle-, and high-income countries. It addresses global challenges in pharmacological headache treatment, with a focus on safety, tolerability, reproductive and child health, and outlines disparities in accessing innovative treatments worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Organized headache services are essential due to the wide prevalence and varying severity of headache disorders. The tiered headache service model is globally recognized, although its implementation varies based on financial and workforce considerations. Headache burden affects well-being, causing disability, economic challenges, and work limitations, irrespective of location or income. All nations still require improved diagnosis and treatment, and the majority of countries face obstacles including limited access, awareness, economic barriers, and inadequate health policies. Provided adequate internet availability, telemedicine could help improve health equity by expanding access to headache care, since it can offer patients access to services without lengthy waiting times or extensive travel and can provide healthcare unavailable in underserved areas due to staff shortages.<\/jats:p>\n                    <jats:p>Numerous health disparities restrict global access to many headache medications, especially impacting individuals historically excluded from randomized controlled trials, such as those with cardiovascular and cerebrovascular conditions, as well as pregnant women. Furthermore, despite advancements in researching migraine treatments for young patients, the options for treatment remain limited.<\/jats:p>\n                    <jats:p>Access to headache treatment relies on factors like medication availability, approval, financial coverage, and healthcare provider expertise. Inadequate public awareness leads to neglect by policymakers and undertreatment by patients and healthcare providers. Global access discrepancies are exacerbated by the introduction of novel disease-specific medications, particularly impacting Asian, African, and Latin American nations excluded from clinical trials. While North America and Europe experience broad availability of migraine treatments, the majority of countries worldwide lack access to these therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Healthcare disparities, treatment access, and medication availability are concerning issues in headache medicine. Variations in national healthcare systems impact headache management, and costly innovative drugs are widening these gaps. Healthcare practitioners and experts should acknowledge these challenges and work towards minimizing access barriers for equitable global headache care in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01699-7","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T19:02:13Z","timestamp":1702407733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Health equity, care access and quality in headache \u2013 part 2"],"prefix":"10.1186","volume":"24","author":[{"given":"Bianca","family":"Raffaelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elo\u00edsa","family":"Rubio-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Icco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Labastida-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Onan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Waliszewska-Pros\u00f3\u0142","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Puledda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"10283","key":"1699_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u20131495","journal-title":"Lancet"},{"issue":"1","key":"1699_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-021-01265-z","volume":"22","author":"TJ Steiner","year":"2021","unstructured":"Steiner TJ, Jensen R, Katsarava Z, Stovner LJ, Uluduz D, Adarmouch L et al (2021) Structured headache services as the solution to the ill-health burden of headache: 1 Rationale and description. J Headache Pain 22(1):78","journal-title":"J Headache Pain"},{"issue":"4","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1474-4422(04)00703-3","volume":"3","author":"TJ Steiner","year":"2004","unstructured":"Steiner TJ (2004) Lifting the burden: The global campaign against headache. Lancet Neurol 3(4):204\u2013205","journal-title":"Lancet Neurol"},{"issue":"1","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19(1):10","journal-title":"J Headache Pain"},{"key":"1699_CR5","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u201359."},{"issue":"1","key":"1699_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10194-011-0398-1","volume":"13","author":"C Lampl","year":"2012","unstructured":"Lampl C, Steiner TJ, Mueller T, Mirvelashvili E, Djibuti M, Kukava M et al (2012) Will (or can) people pay for headache care in a poor country? J Headache Pain 13(1):67\u201374","journal-title":"J Headache Pain"},{"key":"1699_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s10194-015-0574-9","volume":"16","author":"GN Rao","year":"2015","unstructured":"Rao GN, Kulkarni GB, Gururaj G, Stovner LJ, Steiner TJ (2015) The burden attributable to headache disorders in India: estimates from a community-based study in Karnataka State. J Headache Pain 16:94","journal-title":"J Headache Pain"},{"key":"1699_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-015-0549-x","volume":"16","author":"GB Kulkarni","year":"2015","unstructured":"Kulkarni GB, Rao GN, Gururaj G, Stovner LJ, Steiner TJ (2015) Headache disorders and public ill-health in India: prevalence estimates in Karnataka State. J Headache Pain 16:67","journal-title":"J Headache Pain"},{"issue":"9","key":"1699_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S1474-4422(04)00855-5","volume":"3","author":"K Ravishankar","year":"2004","unstructured":"Ravishankar K (2004) Barriers to headache care in India and efforts to improve the situation. Lancet Neurol 3(9):564\u2013567","journal-title":"Lancet Neurol"},{"issue":"1","key":"1699_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-017-0790-6","volume":"18","author":"S Yu","year":"2017","unstructured":"Yu S, Steiner TJ (2017) Lifting the burden of headache in China: managing migraine in a SMART way. J Headache Pain 18(1):79","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-019-1048-2","volume":"20","author":"C Yao","year":"2019","unstructured":"Yao C, Wang Y, Wang L, Liu Y, Liu J, Qi J et al (2019) Burden of headache disorders in China, 1990\u20132017: findings from the global burden of disease study 2017. J Headache Pain 20(1):102","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s10194-019-1036-6","volume":"20","author":"MFP Peres","year":"2019","unstructured":"Peres MFP, Queiroz LP, Rocha-Filho PS, Sarmento EM, Katsarava Z, Steiner TJ (2019) Migraine: a major debilitating chronic non-communicable disease in Brazil, evidence from two national surveys. J Headache Pain 20(1):85","journal-title":"J Headache Pain"},{"issue":"10","key":"1699_CR13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/03331024221093623","volume":"42","author":"M Lisicki","year":"2022","unstructured":"Lisicki M, Souza MNP, de Oliveira AB, Rubio-Beltr\u00e1n E, Labastida-Ramirez A, Ashina M et al (2022) Bridging the gaps of headache care for underserved populations: current status of the headache field in Latin America. Cephalalgia 42(10):1086\u20131090","journal-title":"Cephalalgia"},{"issue":"1","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jval.2021.11.419","volume":"25","author":"S Malhan","year":"2022","unstructured":"Malhan S, Baykan B, Ertas M, Karli N, Oksuz E, Ozge A (2022) POSB146 economic burden of migraine in Turkey. Value in Health 25(1):S89","journal-title":"Value in Health"},{"issue":"3","key":"1699_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27","author":"L Stovner","year":"2007","unstructured":"Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A et al (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3):193\u2013210","journal-title":"Cephalalgia"},{"key":"1699_CR16","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/S1463423618000324","volume":"20","author":"PTG Davies","year":"2019","unstructured":"Davies PTG, Lane RJM, Astbury T, Fontebasso M, Murphy J, Matharu M (2019) The long and winding road: the journey taken by headache sufferers in search of help. Prim Health Care Res Dev 20:e4","journal-title":"Prim Health Care Res Dev"},{"issue":"7","key":"1699_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/0333102421989630","volume":"41","author":"TS Constantinidis","year":"2021","unstructured":"Constantinidis TS, Arvaniti C, Fakas N, Rudolf J, Kouremenos E, Giannouli E et al (2021) A population-based survey for disabling headaches in Greece: prevalence, burden and treatment preferences. Cephalalgia 41(7):810\u2013820","journal-title":"Cephalalgia"},{"issue":"1","key":"1699_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s10194-023-01553-w","volume":"24","author":"TP Do","year":"2023","unstructured":"Do TP, D\u00f8mgaard M, Stefansen S, Steiner TJ, Ashina M (2023) Characterizing healthcare utilization patterns in a Danish population with headache: results from the nationwide headache in Denmark (HINDER) panel. J Headache Pain 24(1):18","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-023-01575-4","volume":"24","author":"M Waliszewska-Pros\u00f3\u0142","year":"2023","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Straburzy\u0144ski M, Czapi\u0144ska-Ciepiela EK, Nowaczewska M, Gryglas-Dworak A, Budrewicz S (2023) Migraine symptoms, healthcare resources utilization and disease burden in a large polish migraine cohort\u202f: results from \u2019migraine in poland\u2019-a nationwide cross-sectional survey. J Headache Pain 24(1):40","journal-title":"J Headache Pain"},{"issue":"9","key":"1699_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache 58(9):1408\u20131426","journal-title":"Headache"},{"issue":"7","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1046\/j.1526-4610.2001.041007638.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF (2001) Migraine diagnosis and treatment: results from the American migraine study II. Headache 41(7):638\u2013645","journal-title":"Headache"},{"issue":"3","key":"1699_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1212\/WNL.60.3.441","volume":"60","author":"RB Lipton","year":"2003","unstructured":"Lipton RB, Scher AI, Steiner TJ, Bigal ME, Kolodner K, Liberman JN et al (2003) Patterns of health care utilization for migraine in England and in the United States. Neurology 60(3):441\u2013448","journal-title":"Neurology"},{"issue":"1","key":"1699_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","volume":"15","author":"TJ Steiner","year":"2014","unstructured":"Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lant\u00e9ri-Minet M et al (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15(1):31","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-019-0964-5","volume":"20","author":"MA Korolainen","year":"2019","unstructured":"Korolainen MA, Kurki S, Lassenius MI, Toppila I, Costa-Scharplatz M, Purmonen T et al (2019) Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. J Headache Pain 20(1):13","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"9","key":"1699_CR26","first-page":"Cd002098","volume":"2015","author":"G Flodgren","year":"2015","unstructured":"Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S (2015) Interactive telemedicine: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2015(9):Cd002098","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1129-2377-15-20","volume":"15","author":"C Tassorelli","year":"2014","unstructured":"Tassorelli C, Farm I, Kettinen H, de la Torre ER, Stretenovic S, Thomas W et al (2014) Access to care\u2013an unmet need in headache management? J Headache Pain 15(1):20","journal-title":"J Headache Pain"},{"issue":"2","key":"1699_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7326\/M20-0132","volume":"173","author":"A Mal\u00e2tre-Lansac","year":"2020","unstructured":"Mal\u00e2tre-Lansac A, Engel CC, Xenakis L, Carlasare L, Blake K, Vargo C et al (2020) Factors influencing physician practices\u2019 adoption of behavioral health integration in the united states: a qualitative study. Ann Intern Med 173(2):92\u201399","journal-title":"Ann Intern Med"},{"issue":"13","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1177\/03331024221111554","volume":"42","author":"TC Clausen","year":"2022","unstructured":"Clausen TC, Greve NK, M\u00fcller KI, Kristoffersen ES, Schytz HW (2022) Telemedicine in headache care: a systematic review. Cephalalgia 42(13):1397\u20131408","journal-title":"Cephalalgia"},{"issue":"3","key":"1699_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14737175.2022.2045954","volume":"22","author":"E Bentivegna","year":"2022","unstructured":"Bentivegna E, Tassorelli C, De Icco R, Sances G, Martelletti P (2022) Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Rev Neurother 22(3):237\u2013243","journal-title":"Expert Rev Neurother"},{"issue":"7","key":"1699_CR31","doi-asserted-by":"publisher","first-page":"e01344","DOI":"10.1002\/brb3.1344","volume":"9","author":"SI Bekkelund","year":"2019","unstructured":"Bekkelund SI, M\u00fcller KI (2019) Video consultations in medication overuse headache A randomized controlled trial. Brain Behav 9(7):e01344","journal-title":"Brain Behav"},{"issue":"12","key":"1699_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1177\/0333102419868250","volume":"39","author":"DI Friedman","year":"2019","unstructured":"Friedman DI, Rajan B, Seidmann A (2019) A randomized trial of telemedicine for migraine management. Cephalalgia 39(12):1577\u20131585","journal-title":"Cephalalgia"},{"issue":"1","key":"1699_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/head.14030","volume":"61","author":"M Smith","year":"2021","unstructured":"Smith M, Nakamoto M, Crocker J, Tiffany Morden F, Liu K, Ma E et al (2021) Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: results of a quality improvement survey. Headache 61(1):149\u2013156","journal-title":"Headache"},{"issue":"7","key":"1699_CR34","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1089\/tmj.2021.0414","volume":"28","author":"V Caponnetto","year":"2022","unstructured":"Caponnetto V, Ornello R, De Matteis E, Papavero SC, Fracasso A, Di Vito G et al (2022) The COVID-19 pandemic as an opportunity to improve health care through a nurse-coordinated multidisciplinary model in a headache specialist center: the implementation of a telemedicine protocol. Telemed J E Health 28(7):1016\u20131022","journal-title":"Telemed J E Health"},{"issue":"7","key":"1699_CR35","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1007\/s10072-021-05212-3","volume":"42","author":"I Rosellini","year":"2021","unstructured":"Rosellini I, Vianello M, Ghazaryan A, Guidoni SV, Palmieri A, Giopato F et al (2021) Virtual visits for chronic neurologic disorders during COVID-19 pandemic. Neurol Sci 42(7):2607\u20132610","journal-title":"Neurol Sci"},{"issue":"3","key":"1699_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/03331024211040753","volume":"42","author":"M Straburzy\u0144ski","year":"2022","unstructured":"Straburzy\u0144ski M, Nowaczewska M, Budrewicz S, Waliszewska-Pros\u00f3\u0142 M (2022) COVID-19-related headache and sinonasal inflammation: A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection. Cephalalgia 42(3):218\u2013228","journal-title":"Cephalalgia"},{"issue":"12","key":"1699_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s11916-022-01096-w","volume":"26","author":"DG Rogers","year":"2022","unstructured":"Rogers DG, Santamaria K, Seng EK, Grinberg AS (2022) Behavioral health, telemedicine, and opportunities for improving access. Curr Pain Headache Rep 26(12):919\u2013926","journal-title":"Curr Pain Headache Rep"},{"issue":"12","key":"1699_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11916-018-0731-3","volume":"22","author":"DR Befus","year":"2018","unstructured":"Befus DR, Irby MB, Coeytaux RR, Penzien DB (2018) A Critical exploration of migraine as a health disparity: the imperative of an equity-oriented, intersectional approach. Curr Pain Headache Rep 22(12):79","journal-title":"Curr Pain Headache Rep"},{"key":"1699_CR39","unstructured":"World Health Organization. Atlas of headache disorders and resources in the world 2011. Geneva: World Health Organization; 2011. https:\/\/www.who.int\/publications\/i\/item\/9789241564212."},{"key":"1699_CR40","doi-asserted-by":"crossref","unstructured":"World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). World Health Organization; 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2021.02.","DOI":"10.1530\/ey.19.13.1"},{"key":"1699_CR41","first-page":"4792","volume":"10","author":"R Rabbie","year":"2010","unstructured":"Rabbie R, Derry S, Moore RA, McQuay HJ (2010) Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 10:4792","journal-title":"Cochrane Database Syst Rev"},{"key":"1699_CR42","first-page":"CD011889","volume":"6","author":"G Stephens","year":"2016","unstructured":"Stephens G, Derry S, Moore RA (2016) Paracetamol (acetaminophen) for acute treatment of episodic tension-type headache in adults. Cochrane Database Syst Rev 6:CD011889","journal-title":"Cochrane Database Syst Rev"},{"key":"1699_CR43","first-page":"CD011888","volume":"1","author":"S Derry","year":"2017","unstructured":"Derry S, Wiffen PJ, Moore RA (2017) Aspirin for acute treatment of episodic tension-type headache in adults. Cochrane Database of Syst Rev 1:CD011888","journal-title":"Cochrane Database of Syst Rev"},{"issue":"5","key":"1699_CR44","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","volume":"161","author":"A Labastida-Ram\u00edrez","year":"2020","unstructured":"Labastida-Ram\u00edrez A, Rubio-Beltr\u00e1n E, Haanes KA, Chan KY, Garrelds IM, Johnson KW et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 161(5):1092\u20131099","journal-title":"Pain"},{"issue":"24","key":"1699_CR45","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1111\/bph.14832","volume":"176","author":"E Rubio-Beltran","year":"2019","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, van den Bogaerdt A, Bogers A, Zanelli E et al (2019) Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol 176(24):4681\u20134695","journal-title":"Br J Pharmacol"},{"key":"1699_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltran","year":"2018","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A (2018) Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88\u201397","journal-title":"Pharmacol Ther"},{"key":"1699_CR47","first-page":"CD008042","volume":"7","author":"S Law","year":"2013","unstructured":"Law S, Derry S, Moore RA (2013) Triptans for acute cluster headache. Cochrane Database Syst Rev 7:CD008042","journal-title":"Cochrane Database Syst Rev"},{"key":"1699_CR48","first-page":"CD009108","volume":"5","author":"CJ Derry","year":"2014","unstructured":"Derry CJ, Derry S, Moore RA (2014) Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 5:CD009108","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"1699_CR49","first-page":"S20","volume":"44","author":"DW Dodick","year":"2004","unstructured":"Dodick DW, Martin VT, Smith T, Silberstein S (2004) Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache 44(Suppl 1):S20-30","journal-title":"Headache"},{"key":"1699_CR50","doi-asserted-by":"crossref","unstructured":"Kalkman DN, Couturier EGM, El Bouziani A, Dahdal J, Neefs J, Woudstra J, et al. Migraine and cardiovascular disease: what cardiologists should know. European Heart Journal. 2023.","DOI":"10.1093\/eurheartj\/ehad363"},{"issue":"s1","key":"1699_CR51","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/j.1526-4610.2004.04104.x","volume":"44","author":"A MaassenVanDenBrink","year":"2004","unstructured":"MaassenVanDenBrink A, Saxena PR (2004) Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache 44(s1):S13\u2013S9","journal-title":"Headache"},{"issue":"12","key":"1699_CR52","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.2165\/11537990-000000000-00000","volume":"70","author":"MM Johnston","year":"2010","unstructured":"Johnston MM, Rapoport AM (2010) Triptans for the management of migraine. Drugs 70(12):1505\u20131518","journal-title":"Drugs"},{"issue":"1","key":"1699_CR53","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12883-021-02451-x","volume":"21","author":"AM Deighton","year":"2021","unstructured":"Deighton AM, Harris LA, Johnston K, Hogan S, Quaranta LA, L\u2019Italien G et al (2021) The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review. BMC Neurol 21(1):425","journal-title":"BMC Neurol"},{"issue":"1","key":"1699_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/brain\/123.1.9","volume":"123","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, Saxena PR, Dahl\u00f6f C, Pascual J, L\u00e1inez M, Henry P et al (2000) Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 123(1):9\u201318","journal-title":"Brain"},{"issue":"5","key":"1699_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/pmt-2022-0063","volume":"13","author":"AJ Starling","year":"2023","unstructured":"Starling AJ, Mallick-Searle T, Shrewsbury SB, Aurora SK (2023) INP104: a drug evaluation of a nonoral product for the acute treatment of migraine. Pain Management 13(5):283\u2013298","journal-title":"Pain Management"},{"issue":"4","key":"1699_CR56","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.annemergmed.2004.07.430","volume":"45","author":"I Colman","year":"2005","unstructured":"Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH (2005) Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature. Ann Emerg Med 45(4):393\u2013401","journal-title":"Ann Emerg Med"},{"issue":"14","key":"1699_CR57","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1177\/0333102419863027","volume":"39","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Dirven C et al (2019) Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia 39(14):1735\u20131744","journal-title":"Cephalalgia"},{"key":"1699_CR58","unstructured":"Ergot derivatives - European Medicines Agency 2020 [updated 2020\/12\/10\/. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/ergot-derivatives#overview-section."},{"key":"1699_CR59","first-page":"CD3225","volume":"2","author":"K Linde","year":"2004","unstructured":"Linde K, Rossnagel K (2004) Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2:CD3225","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1699_CR60","doi-asserted-by":"publisher","first-page":"033310242311831","DOI":"10.1177\/03331024231183166","volume":"43","author":"C Carcel","year":"2023","unstructured":"Carcel C, Haghdoost F, Shen J, Nanda P, Bai Y, Atkins E et al (2023) The effect of blood pressure lowering medications on the prevention of episodic migraine: a systematic review and meta-analysis. Cephalalgia 43(6):03331024231183166","journal-title":"Cephalalgia"},{"issue":"8","key":"1699_CR61","first-page":"1031","volume":"1","author":"R Pozzi","year":"2000","unstructured":"Pozzi R (2000) True and presumed contraindications of beta blockers. Peripheral vascular disease, diabetes mellitus, chronic bronchopneumopathy. Italian Heart J Suppl 1(8):1031\u20137","journal-title":"Italian Heart J Suppl"},{"issue":"4","key":"1699_CR62","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache 53(4):644\u2013655","journal-title":"Headache"},{"issue":"1","key":"1699_CR63","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22\u201333","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"1699_CR64","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14737167.2021.1945444","volume":"22","author":"K Johnston","year":"2022","unstructured":"Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A et al (2022) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res 22(1):155\u2013166","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1699_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-019-1044-6","volume":"20","author":"RE Shapiro","year":"2019","unstructured":"Shapiro RE, Hochstetler HM, Dennehy EB, Khanna R, Doty EG, Berg PH et al (2019) Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials. J Headache Pain 20(1):90","journal-title":"J Headache Pain"},{"issue":"24","key":"1699_CR66","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1111\/bph.14832","volume":"176","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, Haanes KA, van den Bogaerdt A, Bogers AJ, Zanelli E et al (2019) Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan. Br J Pharmacol 176(24):4681\u20134695","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1699_CR67","doi-asserted-by":"publisher","first-page":"033310242311514","DOI":"10.1177\/03331024231151419","volume":"43","author":"F Puledda","year":"2023","unstructured":"Puledda F, Younis S, Huessler E-M, Haghdoost F, Lisicki M, Goadsby PJ et al (2023) Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia 43(3):03331024231151419","journal-title":"Cephalalgia"},{"issue":"12","key":"1699_CR68","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/brainsci12121612","volume":"12","author":"JP Rissardo","year":"2022","unstructured":"Rissardo JP, Caprara ALF (2022) Gepants for acute and preventive migraine treatment: a narrative review. Brain Sci 12(12):1612","journal-title":"Brain Sci"},{"key":"1699_CR69","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/164_2019_204","volume":"255","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, van den Brink AM (2019) Understanding CGRP and cardiovascular risk. Handb Exp Pharmacol 255:131\u2013140","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"1699_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1474-4422(16)30293-9","volume":"16","author":"KG Vetvik","year":"2017","unstructured":"Vetvik KG, MacGregor EA (2017) Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 16(1):76\u201387","journal-title":"Lancet Neurol"},{"issue":"1","key":"1699_CR71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s10194-018-0922-7","volume":"19","author":"Z Delaruelle","year":"2018","unstructured":"Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B et al (2018) Male and female sex hormones in primary headaches. J Headache Pain 19(1):117","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s10194-017-0816-0","volume":"18","author":"A Negro","year":"2017","unstructured":"Negro A, Delaruelle Z, Ivanova TA, Khan S, Ornello R, Raffaelli B et al (2017) Headache and pregnancy: a systematic review. J Headache Pain 18(1):106","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"1699_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10072-014-1744-2","volume":"35","author":"EA MacGregor","year":"2014","unstructured":"MacGregor EA (2014) Migraine in pregnancy and lactation. Neurol Sci 35(Suppl 1):61\u201364","journal-title":"Neurol Sci"},{"issue":"4","key":"1699_CR74","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrneurol.2015.29","volume":"11","author":"S Amundsen","year":"2015","unstructured":"Amundsen S, Nordeng H, Nezvalov\u00e1-Henriksen K, Stovner LJ, Spigset O (2015) Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol 11(4):209\u2013219","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"1699_CR75","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/head.12540","volume":"55","author":"D Tepper","year":"2015","unstructured":"Tepper D (2015) Pregnancy and lactation\u2013migraine management. Headache 55(4):607\u2013608","journal-title":"Headache"},{"issue":"6","key":"1699_CR76","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00023210-200519060-00001","volume":"19","author":"AW Fox","year":"2005","unstructured":"Fox AW, Diamond ML, Spierings EL (2005) Migraine during pregnancy: options for therapy. CNS Drugs 19(6):465\u2013481","journal-title":"CNS Drugs"},{"issue":"6","key":"1699_CR77","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/aogs.14557","volume":"102","author":"K Nilsen","year":"2023","unstructured":"Nilsen K, Staff AC, Krogsrud SK (2023) Paracetamol use in pregnancy: not as safe as we may think? Acta Obstet Gynecol Scand 102(6):652\u2013656","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"7","key":"1699_CR78","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/head.12375","volume":"54","author":"SA Ephross","year":"2014","unstructured":"Ephross SA, Sinclair SM (2014) Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache 54(7):1158\u20131172","journal-title":"Headache"},{"issue":"1","key":"1699_CR79","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","volume":"15","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R et al (2017) Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 15(1):95","journal-title":"BMC Med"},{"issue":"7","key":"1699_CR80","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","volume":"79","author":"MH Bj\u00f8rk","year":"2022","unstructured":"Bj\u00f8rk MH, Zoega H, Leinonen MK, Cohen JM, Dreier JW, Furu K et al (2022) Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol 79(7):672\u2013681","journal-title":"JAMA Neurol"},{"issue":"9","key":"1699_CR81","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2023.2247963","volume":"22","author":"W Wells-Gatnik","year":"2023","unstructured":"Wells-Gatnik W, Martelletti P (2023) Antiseizure medications as migraine preventatives: a call for action for a teratogenic and neurodevelopmental risk removal. Expert Opin Drug Saf 22(9):777\u201381","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1699_CR82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11910-016-0634-9","volume":"16","author":"RE Wells","year":"2016","unstructured":"Wells RE, Turner DP, Lee M, Bishop L, Strauss L (2016) Managing migraine during pregnancy and lactation. Curr Neurol Neurosci Rep 16(4):40","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"1699_CR83","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/acn3.51640","volume":"9","author":"E Rubio-Beltran","year":"2022","unstructured":"Rubio-Beltran E, Schoon RM, van den Berg J, Schuiling-Veninga CCM, Koch BCP, Villalon CM et al (2022) Trigeminovascular effects of propranolol in men and women, role for sex steroids. Ann Clin Transl Neurol 9(9):1405\u20131416","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"1699_CR84","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/head.12064","volume":"53","author":"S Hutchinson","year":"2013","unstructured":"Hutchinson S, Marmura MJ, Calhoun A, Lucas S, Silberstein S, Peterlin BL (2013) Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache 53(4):614\u201327","journal-title":"Headache"},{"issue":"2","key":"1699_CR85","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1212\/WNL.0000000000207375","volume":"101","author":"MF Brin","year":"2023","unstructured":"Brin MF, Kirby RS, Slavotinek A, Adams AM, Parker L, Ukah A et al (2023) Pregnancy outcomes in patients exposed to onabotulinumtoxina treatment: a cumulative 29-year safety update. Neurology 101(2):e103\u2013e113","journal-title":"Neurology"},{"issue":"1","key":"1699_CR86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s10194-020-01196-1","volume":"21","author":"H-T Wong","year":"2020","unstructured":"Wong H-T, Khalil M, Ahmed F (2020) OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients. J Headache Pain 21(1):129","journal-title":"J Headache Pain"},{"key":"1699_CR87","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.maturitas.2020.12.012","volume":"145","author":"LS de Vries","year":"2021","unstructured":"de Vries LS, Rubio-Beltr\u00e1n E, MaassenVanDenBrink A (2021) Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman\u2019s life: Implications for the efficacy and safety of novel antimigraine medications. Maturitas 145:73\u201377","journal-title":"Maturitas"},{"issue":"2","key":"1699_CR88","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1095\/biolreprod67.2.624","volume":"67","author":"PRR Gangula","year":"2002","unstructured":"Gangula PRR, Dong YL, Wimalawansa SJ, Yallampalli C (2002) Infusion of Pregnant Rats with Calcitonin Gene-Related Peptide (CGRP)8\u201337, a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth1. Biol Reprod 67(2):624\u2013629","journal-title":"Biol Reprod"},{"key":"1699_CR89","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.yrtph.2019.05.013","volume":"106","author":"JL Bussiere","year":"2019","unstructured":"Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM et al (2019) Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol 106:224\u2013238","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"1699_CR90","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-018-0898-3","volume":"19","author":"E Vatzaki","year":"2018","unstructured":"Vatzaki E, Straus S, Dogne JM, Garcia Burgos J, Girard T, Martelletti P (2018) Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European medicines agency and european headache federation. J Headache Pain 19(1):68","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","volume":"24","author":"A Onofri","year":"2023","unstructured":"Onofri A, Pensato U, Rosignoli C, Wells-Gatnik W, Stanyer E, Ornello R et al (2023) Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain 24(1):8","journal-title":"J Headache Pain"},{"key":"1699_CR92","first-page":"e230009","volume":"26","author":"VC Lemos","year":"2023","unstructured":"Lemos VC, Barros MBA, Lima MG (2023) Chronic diseases and health conditions in adolescents: sex inequalities. Rev Bras Epidemiol 26:e230009","journal-title":"Rev Bras Epidemiol"},{"issue":"6","key":"1699_CR93","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/MOP.0000000000000694","volume":"30","author":"SK Slater","year":"2018","unstructured":"Slater SK, Powers SW, O\u2019Brien HL (2018) Migraine in children: presentation, disability and response to treatment. Curr Opin Pediatr 30(6):775\u2013779","journal-title":"Curr Opin Pediatr"},{"issue":"9","key":"1699_CR94","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41582-018-0042-7","volume":"14","author":"SL Orr","year":"2018","unstructured":"Orr SL, Kabbouche MA, O\u2019Brien HL, Kacperski J, Powers SW, Hershey AD (2018) Paediatric migraine: evidence-based management and future directions. Nat Rev Neurol 14(9):515\u2013527","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"1699_CR95","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11916-017-0648-2","volume":"21","author":"AM Kroon Van Diest","year":"2017","unstructured":"Kroon Van Diest AM, Ernst MM, Slater S, Powers SW (2017) Similarities and differences between migraine in children and adults: presentation, disability, and response to treatment. Curr Pain Headache Rep 21(12):48","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1699_CR96","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10194-008-0007-0","volume":"9","author":"N Senbil","year":"2008","unstructured":"Senbil N, Gurer YK, Uner C, Barut Y (2008) Sinusitis in children and adolescents with chronic or recurrent headache: a case-control study. J Headache Pain 9(1):33\u201336","journal-title":"J Headache Pain"},{"issue":"10","key":"1699_CR97","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737175.2020.1797493","volume":"20","author":"R Rao","year":"2020","unstructured":"Rao R, Hershey AD (2020) An update on acute and preventive treatments for migraine in children and adolescents. Expert Rev Neurother 20(10):1017\u20131027","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"1699_CR98","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/head.12105","volume":"53","author":"AD Hershey","year":"2013","unstructured":"Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL et al (2013) Childhood and Adolescent Migraine Prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache 53(5):799\u2013816","journal-title":"Headache"},{"issue":"4","key":"1699_CR99","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ncl.2019.07.009","volume":"37","author":"K Greene","year":"2019","unstructured":"Greene K, Irwin SL, Gelfand AA (2019) Pediatric Migraine: An Update. Neurol Clin 37(4):815\u2013833","journal-title":"Neurol Clin"},{"key":"1699_CR100","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.ensci.2022.100427","volume":"29","author":"D Mortel","year":"2022","unstructured":"Mortel D, Kawatu N, Steiner TJ, Saylor D (2022) Barriers to headache care in low- and middle-income countries. eNeurologicalSci 29:100427","journal-title":"eNeurologicalSci"},{"issue":"1","key":"1699_CR101","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-021-01250-6","volume":"22","author":"BK Kim","year":"2021","unstructured":"Kim BK, Chu MK, Yu SJ, Dell\u2019Agnello G, Han JH, Cho SJ (2021) Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain 22(1):45","journal-title":"J Headache Pain"},{"issue":"3","key":"1699_CR102","doi-asserted-by":"crossref","first-page":"033310242311593","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43(3):03331024231159366","journal-title":"Cephalalgia"},{"issue":"10","key":"1699_CR103","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11916-022-01077-z","volume":"26","author":"AM Murray","year":"2022","unstructured":"Murray AM, Stern JI, Robertson CE, Chiang CC (2022) Real-world patient experience of CGRP-targeting therapy for migraine: a narrative review. Curr Pain Headache Rep 26(10):783\u2013794","journal-title":"Curr Pain Headache Rep"},{"issue":"2","key":"1699_CR104","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149","journal-title":"N Engl J Med"},{"issue":"10200","key":"1699_CR105","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 394(10200):737\u2013745","journal-title":"The Lancet"},{"issue":"10268","key":"1699_CR106","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet (London, England) 397(10268):51\u201360","journal-title":"Lancet (London, England)"},{"key":"1699_CR107","unstructured":"National Institute for Health and Care Excellence - Appraisal consultation document. Rimegepant for treating or preventing migraine 2023 [Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta10839\/documents\/129."},{"key":"1699_CR108","unstructured":"National Institute for Health and Care Excellence - Final appraisal document. Rimegepant for preventing migraine 2023 [Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta11322\/documents\/final-appraisal-determination-document-2."},{"issue":"12","key":"1699_CR109","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11916-018-0731-3","volume":"22","author":"DR Befus","year":"2018","unstructured":"Befus DR, Irby MB, Coeytaux RR, Penzien DB (2018) A critical exploration of migraine as a health disparity: the imperative of an equity-oriented, intersectional approach. Curr Pain Headache Rep 22(12):79","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"1699_CR110","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1212\/01.WNL.0000110312.36809.7F","volume":"62","author":"GC Hall","year":"2004","unstructured":"Hall GC, Brown MM, Mo J, MacRae KD (2004) Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62(4):563\u2013568","journal-title":"Neurology"},{"issue":"1","key":"1699_CR111","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C et al (2023) Medication overuse headache. Nat Rev Dis Primers 9(1):5","journal-title":"Nat Rev Dis Primers"},{"issue":"10283","key":"1699_CR112","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A et al (2021) Migraine: epidemiology and systems of care. The Lancet 397(10283):1485\u20131495","journal-title":"The Lancet"},{"key":"1699_CR113","unstructured":"National Institute for Health and Care Excellence - Rimegepant for treating migraine 2023 [cited 2023 18\/10]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta919."},{"key":"1699_CR114","doi-asserted-by":"publisher","first-page":"18006","DOI":"10.1038\/nrdp.2018.6","volume":"4","author":"A May","year":"2018","unstructured":"May A, Schwedt TJ, Magis D, Pozo-Rosich P, Evers S, Wang SJ (2018) Cluster headache. Nat Rev Dis Primers 4:18006","journal-title":"Nat Rev Dis Primers"},{"key":"1699_CR115","doi-asserted-by":"publisher","first-page":"827734","DOI":"10.3389\/fneur.2022.827734","volume":"13","author":"BS Kim","year":"2022","unstructured":"Kim BS, Chung PW, Kim BK, Lee MJ, Chu MK, Ahn JY et al (2022) Diagnostic delay and its predictors in cluster headache. Front Neurol 13:827734","journal-title":"Front Neurol"},{"issue":"2","key":"1699_CR116","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40122-021-00278-5","volume":"10","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Curto M (2021) Cluster headache is still lurking in the shadows. Pain Ther 10(2):777\u2013781","journal-title":"Pain Ther"},{"issue":"1\u20132","key":"1699_CR117","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2012.03.006","volume":"317","author":"TD Rozen","year":"2012","unstructured":"Rozen TD, Fishman RS (2012) Female cluster headache in the United States of America: what are the gender differences? Results from the United States cluster headache survey. J Neurol Sci 317(1\u20132):17\u201328","journal-title":"J Neurol Sci"},{"issue":"1","key":"1699_CR118","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1129-2377-14-30","volume":"14","author":"G Mengistu","year":"2013","unstructured":"Mengistu G, Alemayehu S (2013) Prevalence and burden of primary headache disorders among a local community in Addis Ababa, Ethiopia. J Headache Pain 14(1):30","journal-title":"J Headache Pain"},{"issue":"7","key":"1699_CR119","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/head.12866","volume":"56","author":"MS Robbins","year":"2016","unstructured":"Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ (2016) Treatment of cluster headache: the american headache society evidence-based guidelines. Headache 56(7):1093\u20131106","journal-title":"Headache"},{"issue":"1","key":"1699_CR120","doi-asserted-by":"publisher","first-page":"7","DOI":"10.11607\/ofph.2223","volume":"34","author":"P Rossi","year":"2020","unstructured":"Rossi P, De La Torre ER, Mitsikostas D, Di Lorenzo C, Palmaro A (2020) Availability of effective evidence-based symptomatic treatments for cluster headache in the EU countries-a survey of the European headache alliance and european headache federation. J Oral Facial Pain Headache 34(1):7\u201312","journal-title":"J Oral Facial Pain Headache"},{"issue":"3","key":"1699_CR121","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3988\/jcn.2022.18.3.271","volume":"18","author":"H Mo","year":"2022","unstructured":"Mo H, Chung SJ, Rozen TD, Cho S-J (2022) Oxygen therapy in cluster headache, migraine, and other headache disorders. J Clin Neurol 18(3):271\u2013279","journal-title":"J Clin Neurol"},{"issue":"4","key":"1699_CR122","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/0333102416647786","volume":"37","author":"S Evers","year":"2017","unstructured":"Evers S, Rapoport A (2017) The use of oxygen in cluster headache treatment worldwide \u2013 a survey of the International Headache Society (IHS). Cephalalgia 37(4):396\u2013398","journal-title":"Cephalalgia"},{"issue":"1","key":"1699_CR123","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1129-2377-15-79","volume":"15","author":"DD Mitsikostas","year":"2014","unstructured":"Mitsikostas DD, Edvinsson L, Jensen RH, Katsarava Z, Lampl C, Negro A et al (2014) Refractory chronic cluster headache: a consensus statement on clinical definition from the European headache federation. J Headache Pain 15(1):79","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR124","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/brainsci10010030","volume":"10","author":"A Carmine Belin","year":"2020","unstructured":"Carmine Belin A, Ran C, Edvinsson L (2020) Calcitonin Gene-Related Peptide (CGRP) and cluster headache. Brain Sci 10(1):30","journal-title":"Brain Sci"},{"issue":"2","key":"1699_CR125","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA et al (2019) Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med 381(2):132\u2013141","journal-title":"N Engl J Med"},{"issue":"9","key":"1699_CR126","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","volume":"40","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM et al (2020) Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment. Cephalalgia 40(9):935\u2013948","journal-title":"Cephalalgia"},{"key":"1699_CR127","unstructured":"FDA News Release. FDA approves first treatment for episodic cluster headache that reduces the frequency of attacks. 2019 [Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-episodic-cluster-headache-reduces-frequency-attacks#:~:text=Emgality%20is%20given%20by%20patient,treatment%20of%20migraine%20in%20adults."},{"key":"1699_CR128","unstructured":"European Medicines Agency. Refusal of a change to the marketing authorisation for Emgality (galcanezumab) [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/questions-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_en.pdf."},{"issue":"14","key":"1699_CR129","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","volume":"40","author":"R Ruscheweyh","year":"2020","unstructured":"Ruscheweyh R, Broessner G, Go\u00dfrau G, Heinze-Kuhn K, J\u00fcrgens TP, Kaltseis K et al (2020) Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts. Cephalalgia 40(14):1574\u20131584","journal-title":"Cephalalgia"},{"issue":"10","key":"1699_CR130","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/head.14404","volume":"62","author":"JA Membrilla","year":"2022","unstructured":"Membrilla JA, Torres-Ferrus M, Alpuente A, Caronna E, Pozo-Rosich P (2022) Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review. Headache 62(10):1395\u20131405","journal-title":"Headache"},{"issue":"1","key":"1699_CR131","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-022-01505-w","volume":"23","author":"H Mo","year":"2022","unstructured":"Mo H, Kim B-K, Moon H-S, Cho S-J (2022) Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache. J Headache Pain 23(1):132","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR132","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10072-021-05624-1","volume":"43","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Geppetti P, De Cesaris F (2022) Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series. Neurological Sci 43(1):697\u2013703","journal-title":"Neurological Sci"},{"issue":"1","key":"1699_CR133","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/neurolint15010020","volume":"15","author":"K Kashiwagi","year":"2023","unstructured":"Kashiwagi K, Katsuki M, Kawamura S, Tachikawa S, Ono A, Koh A (2023) Fremanezumab and non-high-dose galcanezumab for comorbid cluster headache in patients with migraine: three cases. Neurol Int 15(1):318\u2013324","journal-title":"Neurol Int"},{"issue":"1","key":"1699_CR134","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-023-01666-2","volume":"24","author":"P Martelletti","year":"2023","unstructured":"Martelletti P, Leonardi M, Ashina M, Burstein R, Cho SJ, Charway-Felli A et al (2023) Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain 24(1):140","journal-title":"J Headache Pain"},{"issue":"8","key":"1699_CR135","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s42399-020-00394-x","volume":"2","author":"MW Ali","year":"2020","unstructured":"Ali MW, Musami UB, Sa\u2019ad FK, Omoaghe C, Danimoh MA, Ayoola YA et al (2020) Profile of migraine patients in a developing country: a multicentre study. SN Comprehensive Clin Med 2(8):1153\u20137","journal-title":"SN Comprehensive Clin Med"},{"issue":"1","key":"1699_CR136","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s42399-021-01091-z","volume":"4","author":"YH Lau","year":"2022","unstructured":"Lau YH, Kurien JK, Lau KM, Adenan S (2022) Clinical profile of migraine patients: a descriptive study of a single tertiary centre in Malaysia. SN Comprehensive Clin Med 4(1):22","journal-title":"SN Comprehensive Clin Med"},{"key":"1699_CR137","first-page":"1","volume":"9","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Galastri S, Onan D, Martelletti P (2023) Unmet needs in the acute treatment of migraine. Adv Ther 9:1\u20133","journal-title":"Adv Ther"},{"issue":"2","key":"1699_CR138","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40120-023-00438-z","volume":"12","author":"E Bentivegna","year":"2023","unstructured":"Bentivegna E, Onan D, Martelletti P (2023) Unmet needs in preventive treatment of migraine. Neurol Ther 12(2):337\u2013342","journal-title":"Neurol Ther"},{"issue":"6","key":"1699_CR139","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.3390\/ijerph20065186","volume":"20","author":"P Martelletti","year":"2023","unstructured":"Martelletti P (2023) One health for headaches: a clinical scientist residence project. Int J Environ Res Public Health 20(6):5186","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1699_CR140","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-023-01573-6","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, Versijpt J, Amin FM, Deligianni CI, Gil-Gouveia R, Jassal T et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 1: amitriptyline. J Headache Pain 24(1):39","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR141","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","volume":"24","author":"CI Deligianni","year":"2023","unstructured":"Deligianni CI, Sacco S, Ekizoglu E, Uluduz D, Gil-Gouveia R, MaassenVanDenBrink A et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine. J Headache Pain 24(1):128","journal-title":"J Headache Pain"},{"issue":"1","key":"1699_CR142","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Garc\u00eda-Azor\u00edn D, Boucherie DM, Amin FM, Deligianni CI, Gil-Gouveia R et al (2023) European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate. J Headache Pain 24(1):134","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01699-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:02:28Z","timestamp":1702425748000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":142,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01699-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"28 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BR reports personal fees from Abbvie, Eli Lilly, Lundbeck, Novartis and Teva for participating in advisory boards and\/or speaker activities as well as research funding from Novartis.SJC reports personal fees from Korea Otsuka Pharmaceutical, Boryung Pharmaceutical Co.,Ltd., Pfizer Ltd, Yuyu Pharmaceutical Company, Eli Lilly and Company, Allergan Korea, Abbvie Inc, SK chemicals, Teva-Handok company, Hyundaipharm. Co. Ltd, and H. Lundbeck A\/S (Lundbeck) for advisory boards and speaker activities as well as research funding from Biohaven Asia Pacific Ltd, Allergan Korea, Abbvie Inc., Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company, Hyundaipharm. Co. Ltd,, SK chemicals, Teva-Handok company, and Lundbeck A\/S (Lundbeck).RDI reports personal fees from Eli Lilly, TEVA, Lundbeck for speaker activities.ALR has no conflict of interest.DO has no conflict of interest.RO reports personal fees from Abbvie, Eli Lilly, Novartis, Pfizer, and Teva for advisory boards and speaker activities and non-financial support from Novartis and Teva.ERB has no conflict of interest.RR reports travel grants and\/or honoraria for lectures or advisory boards from Allergan\/AbbVie, Hormosan, Lilly, Lundbeck, Novartis and Teva.MWP reports personal fees from Abbvie, Pfizer and Teva for speaker activities.RM reports personal fees from Eli-Lilly for participating in advisory boards and speaker activities.FP reports personal fees from TEVA for speaker activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}